Slide 1

A REVISIT TO MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOUR (GIST) Joint Hospital Surgical Grand Round 17 Jan 2015 Grace Liu Pamela Youde Nethersole Eastern Hospital

Slide 2

INTRODUCTION Surgical management is indicated whenever possible because it is the only potentially curative option High risk GISTs 36 months adjuvant target therapy (imatinib)

Slide 3

HOW TO DEAL WITH SMALL GISTS? When we saw a small submucosal mass, what should we do?

Slide 4

Small GIST

LAPAROSCOPIC RESECTION for small tumours 90% Studies have shown laparoscopic resections of tumours up to 6cm with low recurrence rates and margin negativity Koh, Y.X. et al. Annals of Surgical Oncology, 20, 3549-3560.

Slide 9

Overall survivalDisease free survival Size >5-10cm DA Bischof et al

Slide 10

High risk GIST after resection should receive adjuvant imatinib for 36 months

Slide 11

A TUMOUR TOO LARGE

Slide 12

NEOADJUVANT THERAPY Aim: reduce tumor size to facilitate R0 resection and increase the likelihood of organ preservation may decrease the risk of bleeding, postoperative complications, or tumour rupture unresectable or borderline resectable primary tumour potentially resectable tumour that requires extensive surgery local recurrence of locally advanced disease NCCN Clinical Practice Guideline in Oncology. ESMO Clinical Practice

Slide 13

Imatinib is given 2-6 months before surgery Interval assessment of response by PET scan Before SUV=17.3 3 weeks after SUV=5.8

Slide 14

P Rutkowski et al Retrospective analysis of 10 EORTC centres, 161 patients with locally advanced, non-metastatic GIST Only 2 patients have disease progression during pre- operative phase R0 resection 83%, 5 yr DSS 95%

Slide 15

CONCLUSION Surgery for resectable GISTs, laparoscopic resection for tumours